Intelligence Platform

Patents

Browse 750 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11186646

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11186873

Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (I

Wellmarker Bio Co., LTD. · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11180562

Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-r

CytomX Therapeutics, Inc. · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11168316

Chimeric clotting factors

BIOVERATIV THERAPEUTICS INC. · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11160850

Compositions of human prothrombin and activated factor X for improving hemostasis in the t

Takeda Pharmaceutical Company Limited · Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11141465

Method of making a water-soluble polymer-factor VIII moiety conjugate

Nektar Therapeutics · Granted Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11135283

Retroviral vector for the administration and expression of replicon RNA expressing heterol

IMMUNE DESIGN CORP. · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11129908

Gene therapy vectors for treating heart disease

Tenaya Therapeutics, Inc. · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11097012

Biodegradable vectors for efficient RNA delivery

The Regents of the University of California · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11091534

Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof

BIOVERATIV THERAPEUTICS INC. · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11083801

Factor VIII mutation repair and tolerance induction

The United States Government Represented by the Departrment of Veteran Affairs · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11078264

Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birt

UNIVERSITY OF CONNECTICUT · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11077108

Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-t

The Regents of the University of California · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11078286

Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066670

Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066481

Antibodies to coagulation factor XIa and uses thereof

The Regents of the University of California · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11060110

Adeno-associated virus vectors for treatment of glycogen storage disease

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11058664

In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pe

Provectus Pharmatech, Inc. · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11040125

Neurotrophic factor carrier, method for producing the same, and method for regenerating a

Wiregene Co., Ltd. · Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11034740

Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and the

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11028160

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11028161

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11028444

Survival predictor for diffuse large B cell lymphoma

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11020458

Factor VIII polymer conjugates

Takeda Pharmaceutical Company Limited · Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted